TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: High Flow Nasal Cannula for Obstructive Sleep Apnea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Apnea hypopnea index greater than 5 times per hour~* Age greater than 18 years old.~Exclusion Criteria:~* Central sleep apnea~* Hypoventilation syndrome~* Chronic obstructive airway disease~* Receive soft palate surgery or used an oral appliance~* Intolerance to transnasal high flow or CPAP~* Pregnant women~* Unstable hemodynamic state~* Eastern Cooperative Oncology Group Performance Status higher than grade 2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- First night HFNC group (Type: EXPERIMENTAL): The first night will receive high flow nasal cannula (HFNC) therapy and the second night accept continuous positive airway pressure (CPAP) therapy.
- First night CPAP group (Type: ACTIVE_COMPARATOR): In contrast, the first night will receive continuous positive airway pressure and the second accept high flow nasal cannula therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 9-36 months of either sex, any race, any ethnicity at the time of the initial visit~* EITHER a positive skin prick test to peanuts or in vitro \[CAP-FEIA\] peanut immunoglobin E (IgE) level in the blood \> 0.35 kU/L PLUS a history of a clinical allergic reaction (defined as significant clinical symptoms occurring within 60 minutes after ingesting peanuts) within 6 months of screening~* OR a positive prick skin test to peanuts and in vitro \[CAP-FEIA\] peanut IgE level \> 5 kU/L when there is no history of allergic reaction and no known peanut exposure~* Provision of signed informed consent~* Development of symptoms characteristic of IgE-mediated food allergy (urticaria, angioedema, respiratory distress/wheeze/cough, vomiting/diarrhea, anaphylaxis) during initial oral food challenge~Exclusion Criteria:~* History of severe anaphylaxis to peanut as defined by hypoxia, hypotension, or neurological compromise~* Currently participating in a study using an investigational new drug~* Participation in any interventional study for the treatment of food allergy in the past 12 months~* Subjects with a known wheat food allergy will be excluded because of cross contamination of oat with wheat~* Severe atopic dermatitis~* Currently being treated with greater than medium daily doses of inhaled corticosteroids, as defined by the National Heart Lung and Blood Institute (NHLBI) guidelines~* Inability to discontinue antihistamines for skin testing and OFCs

- Gender: ALL
- Minimum Age: 9 Months
- Maximum Age: 36 Months
- Healthy Volunteers: f

Study Arms:
- Peanut oral immunotherapy (Type: EXPERIMENTAL): Newly diagnosed allergic children receiving peanut flour as oral immunotherapy for the treatment of peanut allergy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* clinical diagnosis of chronic osteoarthritis of the hip or knee for 1 year or longer.~* an average pain due to osteoarthritis of moderate, moderately-severe, or severe for the 14 days prior to enrollment.~Exclusion Criteria:~* ingest opioid analgesics on a daily basis.~* ingest \>2500 milligrams (mg) acetaminophen on a daily basis.~* require \<20 mg or \>80 mg of morphine (or opioid equivalents) per day for control of their osteoarthritis pain.~Other protocol-specific exclusion/inclusion criteria may apply.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BTDS (Type: EXPERIMENTAL): Buprenorphine transdermal patch 5, 10 or 20 micrograms/hour (mcg/h)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to match BTDS 5, 10 or 20 mcg/h

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Narcoleptic with cataplexy : at least 3 weekly cataplexy attacks~* ESS \> or = 12~* ICF signed and dated~Main Exclusion Criteria:~* Other conditions that could generate EDS~* Psychological and neurological disorders~* Acute or chronic severe disease~* Treatment by prohibited medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pitolisant (Type: EXPERIMENTAL): Pitolisant at 5, 10, 20 or 40mg
- Placebo (Type: PLACEBO_COMPARATOR): Capsules of placebo containing lactose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effects of Different Interventions on Glycemic Control in Newly-Diagnosed Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. informed consents be given before treatment~2. the newly-diagnosed type 2 diabetic patients~3. fasting blood glucose (FBG) level ranging from 7.0～16.7 mmol/L~4. age ranging from 25～70 years old~5. body mass index (BMI) ranging from20～35kg/m2~6. never be treated with any anti-hyperglycemic agents or anti-hyperlipidemic agents~Exclusion Criteria:~1. having any severe acute or chronic complications~2. renal dysfunction, blood creatinine≥150µmol/L~3. blood aminotransferase level rising up(more than 2 times of the normal level)~4. any severe cardiac disease including congestive cardiac failure, unstable angina and myocardial infarct in 12 months~5. serious hypertension (systolic pressure≥180mmHg and/ or diastolic pressure≥110mmHg)~6. chronic or acute pancreatic disease~7. severe systematic diseases or malignant tumor~8. allergic to the drugs using in the trial~9. any factors interfering the result~10. female patients incline to be pregnant~11. being treated with corticosteroid, immunosuppressing drugs or cytotoxic drugs~12. poor compliance

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- CSII (Type: ACTIVE_COMPARATOR): Patients in continuous subcutaneous insulin infusion group received Human Insulin (Novolin-R, Novo Nordisk) with an insulin pump (H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland);
- MDI (Type: ACTIVE_COMPARATOR): Patients in MDI group were treated with pre-meal Novolin-R, and Human Insulin NPH (Novolin-N, Novo Nordisk) at bedtime. Initial insulin doses were 0.4-0.5 IU/kg and total daily doses were divided into 50% of basal and 50% of bolus injection in CSII group and 30%-20%-20%-30% in multiple daily insulin injection group
- OHA (Type: ACTIVE_COMPARATOR): In oral hpoglycemic agents group, the patients with 20 kg/m2\<BMI≤25kg/m2 were initiated with Gliclazide (Diamicron, Servier) 80mg Bid (maximum to 160mg Bid), the patients with 25kg/m2\<BMI≤35kg/m2 were initiated with Metformin (Glucophage, BMS) 0.5 Bid (maximum to 2.0g/d), the combination of Diamicron and Glucophage was used in patients who could not achieve glycaemic control goal with one OHA or with FPG≥11.1mmol/l at randomization

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects on Small Airways of Two Long-term Extrafine Treatments in Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Moderate persistent bronchial asthma according to GINA guidelines~Exclusion Criteria:~Associated respiratory diseases Smoking history Oral corticosteroid in the previous six months Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SF (Type: ACTIVE_COMPARATOR): Extrafine Fluticasone/Salmeterol
- FB (Type: ACTIVE_COMPARATOR): Extrafine Formoterol and beclometasone HFA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria for Subjects 9 - 40 Years of Age:~* Healthy~* Properly informed about the study and having signed the informed consent form~* Subject/Parent will commit themselves to comply with the instructions of the investigator and the schedule of the trial.~Inclusion Criteria for Subjects 6 Months - 8 Years of Age:~* Healthy~* Parents have been informed properly regarding the study and signed the informed consent form~* Parents will commit themselves to comply with the instructions of the investigator and the schedule of the trial~Exclusion Criteria:~* Subject concomitantly enrolled or scheduled to be enrolled in another trial~* Evolving mild, moderate or severe illness, especially infectious diseases or fever (axillary temperature \>= 37.5 C )~* Known history of allergy to egg and or chicken protein or any component of the vaccines~* History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection~* Subject who has received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products or long term corticotherapy (\> 2 weeks).~* Pregnancy \& Lactation (Adult)~* Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives~* Subject already immunized with influenza vaccine within 1 year.~* Subjects receive any vaccination within 1 month before and after immunization of Quadrivalent Influenza Vaccine.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- QIV batch 1 (Type: EXPERIMENTAL): 1 dose of 0.5 ml of quadrivalent influenza vaccine batch 1
- QIV batch 2 (Type: EXPERIMENTAL): 1 dose of 0.5 ml of quadrivalent influenza vaccine batch 2
- QIV batch 3 (Type: EXPERIMENTAL): 1 dose of 0.5 ml of quadrivalent influenza vaccine batch 3
- Trivalent Influenza Vaccine (Type: ACTIVE_COMPARATOR): 1 dose of 0.5 ml of trivalent influenza vaccine
- QIV (subjects 6-35 months) (Type: EXPERIMENTAL): 2 dose of 0.25 ml of quadrivalent influenza vaccine
- QIV (subjects 3-8 years) (Type: EXPERIMENTAL): 2 dose of 0.5 ml of quadrivalent influenza vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adalimumab in Severe and Acute Sciatica

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients older than 18~2. Episode of radicular pain in one lower limb for less than 12 weeks.~3. Medical evaluation requiring hospitalisation because of pain or functional handicap~4. Patients presenting a characteristic leg pain in the L3, L4, L5, or S1 territories plus at least one of the following: :~   * positive straight-leg-raising test with an elevation of less than 70°~  * positive femoral stretched~  * clear clinical sign of nerve root involvement~     * muscle strength deficiency or~    * sensory disturbances in clear cut dermatome or~    * lower limb reflex asymmetry.~5. Oswestry score greater than 50~6. If there is a past history of radicular pain involving the same nerve root, a 6 months interval free of leg pain is required.~7. A confirmed herniated disc on usual imaging techniques (CT scan or MRI) in the vicinity of the clinically involved nerve root that has been performed within the last 2 years.~8. Written informed consent~Exclusion Criteria:~1. The presence of recent (\<48 hours) severe muscle weakness (\<3/5) or clinical signs of cauda equina compression, requiring immediate surgery.~   * If surgical procedure is required but is denied, either because of surgeon's decision or because of patient's fully informed decision, then this patient could be included in the protocol.~2. Comorbidities such as :~   * Coexisting infections (Chest X-ray will be performed to all patients and tuberculin skin test in case of doubt concerning a past history of tuberculous infection).~  * Autoimmune disease (other than RA).~  * History of cancer or malign lymphoproliferative disorders (unless the patient has been declared in remission for more than 5 years)~  * History of demyelinating disorders.~3. Pregnancy.~4. History of intolerance to adalimumab or any of its ingredients~5. Previous participation in this clinical study.~6. Participation in another clinical study within 4 weeks prior to the start of or during this study.~7. Poor motivation or other emotional or intellectual problems that are likely to limit the ability of the patient to comply with the protocol requirements.~8. The use of cortisone prior to the inclusion IS NOT an exclusion criteria~The investigators will also be allowed to exclude an individual patient from the study and remove the blinding in case of a superimposed infection or any severe side effect during the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab (Type: EXPERIMENTAL): adalimumab (2 subcutaneous 40 mg injections on day 0 and 7)
- Placebo (Type: PLACEBO_COMPARATOR): 2 placebo injections on day 0 and 7

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject must have a clinical diagnosis to apply the conservative medication for chronic hepatitis C.~2. Serum alanine aminotransferase levels measured at 4-week before the initiation of treatment must be over 61 IU/mL.~3. Subject's age must be 20 years or older.~Exclusion Criteria:~1. Subject who received a treatment of antiviral agents (interferon) within 20 weeks before the start of 8-week observation period~2. Subject who received a treatment of corticosteroids, immunosuppressive drugs, glycyrrhizic acid, cholestyramine or other drugs which could interfere with hepatic function during 8-week observation period.~3. Subject with decompensated cirrhosis~4. Subject infecting with other hepatic virus~5. Subject receiving a treatment for autoimmune disease, alcohol or drug-induced hepatic disorder, neoplasia, hepato-cholangiolar disease, fulminant hepatitis or peptic ulcer~6. Subject who require hospitalization for complications of the heart, kidney or pancreas~7. Pregnancy~8. Alcoholics~9. Alcohol intake more than 27 ml/day~10. Subject who involved in other clinical trial within 4 weeks before the start of observation period~11. Subject with a history of sensitivity to ursodeoxycholic acid or bile acid-products

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ursodeoxycholic acid 150mg / day (Type: EXPERIMENTAL): None
- Ursodeoxycholic acid 600mg / day (Type: EXPERIMENTAL): None
- Ursodeoxycholic acid 900mg / day (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ibuprofen Lozenge in Acute Sore Throat Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male or female aged at least 18 years old~* patient with an acute sore throat~Exclusion Criteria:~* Severe respiratory tract infection (pneumonia, bronchitis or laryngitis)~* Oro-pharyngeal paresthesia or mycosis~* Severely traumatised and/or very severe oromucosal inflammation~* Tonsillopharyngectomy~* Peritonsillar abscess~* Hypersensitivity to ibuprofen or other NonSteroidal Anti-Inflammatory Drugs (NSAIDs) (including bronchospasm) or to excipients~* Long term use (≥ 3 times per week within the last month or regular intake within the last 3 months before randomisation) of antiinflammatory drugs- Any long-acting or slow release analgesic intake including NonSteroidal Anti-Inflammatory Drugs (NSAIDs)within 24 hours before randomisation (e.g. piroxicam or naproxen)~* Any anti-inflammatory drugs intake by systemic route within 12 hours before randomisation~* Any paracetamol intake within 6 hours before randomisation~* Any cold medication (decongestant, antihistamine, expectorant, antitussive) within 6 hours before randomisation~* Any topical throat medication intake containing or not a local oral anaesthetic such as lozenge, spray, mouth rinse within 4 hours before randomisation~* Heavy smokers (\>20 cigarettes/day)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Drug (Type: EXPERIMENTAL): V0498, Ibuprofen 25 mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Local Anaesthetic Dilution on the Characteristics of Ultrasound Guided Axillary Brachial Plexus Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA 1-3~* Patients aged \>18 years undergoing elective upper limb (forearm or hand) surgical procedures.~Exclusion Criteria:~* Contraindications to regional anaesthesia~* Hypersensitivity to amide local anaesthetics.~* Chronic pain~* Language barrier~* Neuromuscular disorders or peripheral neuropathy~* Body mass index \> 35~* History of hepatic and renal insufficiency~* Pregnancy~* Cognitive or psychiatric disorder~* Cardiac conduction abnormality.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 20 ml of lidocaine 2% with epinephrine (Type: ACTIVE_COMPARATOR): Patients will receive axillary brachial plexus block with 20 ml of lidocaine 2% with epinephrine.
- 40 ml 0f lidocaine 1% with epinephrine (Type: EXPERIMENTAL): Patients will receive axillary brachial plexus block with 20 ml of lidocaine 1% with epinephrine diluted with 20 ml of nacl 0.9% ( total 40 ml)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Key Inclusion Criteria:~* Patients must be able to understand and agree to/comply with the prescribed dosing regimens and procedures, report for regularly scheduled study visits, and reliably communicate with study personnel about adverse events and concomitant medications~* Patients chronically infected with hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6, as documented by positive HCV RNA at screening~* Patients who are HCV treatment-naive~* Patients who are HCV treatment-experienced and who have had prior anti-HCV therapies discontinued or completed at least 12 weeks prior to screening~* Patients with HCV RNA ≥10,000 IU/mL at screening~* Patients with HIV-1 infection~Key Exclusion Criteria:~* Presence of AIDs-defining opportunistic infections, as defined by the Centers of Disease Control and Prevention, within 12 weeks prior to study entry~* Patients infected with HIV-2~* Liver or any other organ transplant (including hematopoietic stem cell transplants) other than cornea and hair~* Current or known history of cancer (except in situ carcinoma of the cervix or adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior to screening~* Documented or suspected hepatocellular carcinoma, as evidenced by previously obtained imaging studies or liver biopsy (or on a screening imaging study/liver biopsy if this was performed~* Evidence of decompensated liver disease, including radiologic criteria, a history or presence of ascites, bleeding varices, or hepatic encephalopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Daclatasvir + Sofosbuvir (Treatment-naive) 12 weeks (Type: EXPERIMENTAL): Treatment-naïve participants received daclatasvir 30, 60, or 90 mg, and sofosbuvir, 400 mg, once daily for 12 weeks
- Daclatasvir + Sofosbuvir (Treatment-naive) 8 weeks (Type: EXPERIMENTAL): Treatment-naïve participants received daclatasvir, 30, 60, or 90 mg, and sofosbuvir, 400 mg, once daily for 8 weeks
- Daclatasvir + Sofosbuvir (Treatment-experienced) 12 weeks (Type: EXPERIMENTAL): Treatment-experienced participants received daclatasvir, 30, 60, or 90 mg, and sofosbuvir, 400 mg, once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete